Abstract: Compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein P, P?, W, R1, R2, n, p, q, r, s and t are as defined in the specification, processes for preparing such compounds, pharmaceutical compositions comprising such compounds and their use in therapy.

Abstract: Compounds of the formula (I) are inhibitors of the enzyme Lp-PLA2 and are of use in therapy, in particular for treating atherosclerosis.

Abstract: In a process for the production of uranium tetrafluoride (UF.sub.4), uranic oxides, UO.sub.3 and U.sub.3 O.sub.8, are dissolved in dilute sulphuric acid (H.sub.2 SO.sub.4) and hydrofluoric acid (HF) is added to produce a uranyl fluoride-sulphate solution which is electrolytically reduced to uranous fluoride-sulphate complexes from which hydrated uranium tetrafluoride is precipitated by the addition of dilute HF at elevated temperature (preferably above 90.degree. C.). The uranyl fluoride-sulphate solution can alternatively be produced by dissolving uranyl fluoride in H.sub.2 SO.sub.4 or from uranyl sulphate solutions (derived from solvent extraction or ion exchange purification processes) conditioned with HF.